DEDUCT | Database of Endocrine Disrupting chemicals and their Toxicity profiles

Finasteride

No ToxCast endpoints for intended target type: RNA

ToxCast endpoints for intended target type: Protein

Assay Name	Tissue	Organism	Target Gene ID	Target HGNC Symbol	Response	AC50 Value
CCTE_Deisenroth_5AR_NBTE_ratio	Kidney	Human	6716	SRD5A2	Inhibitory	0.01 μM
ATG_MRE_CIS	Liver	Human	4520	MTF1	Inhibitory	68.27 μM
ATG_NRF2_ARE_CIS	Liver	Human	4780	NFE2L2	Activatory	100.0 μM
ATG_p53_CIS	Liver	Human	7157	TP53	Inhibitory	38.67 μM
ATG_PXRE_CIS	Liver	Human	8856	NR1I2	Inhibitory	14.11 μM
ATG_LXRa_TRANS	Liver	Human	10062	NR1H3	Gain	34.75 μM
ATG_PXR_TRANS	Liver	Human	8856	NR1I2	Gain	19.84 μM
ATG_mPXR_XSP1	Liver	Human	8856	NR1I2	Gain	3.8 μM
ATG_hERa_XSP2	Liver	Human	2099	ESR1	Gain	32.69 μM
ATG_mPXR_XSP2	Liver	Human	8856	NR1I2	Gain	2.09 μM
TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881	Breast	Human	367	AR	Loss	4.46 μM
TOX21_ERR_LUC_Antagonist	Kidney	Human	2101	ESRRA	Loss	20.74 μM
TOX21_PXR_LUC_Agonist	Liver	Human	8856	NR1I2	Gain	23.04 μM
TOX21_p450_CYP2C19_Antagonist		Human	1557	CYP2C19	Loss	1.55 μM
TOX21_p450_CYP2C9_Antagonist		Human	1559	CYP2C9	Loss	2.38 μM
TOX21_AR_BLA_Antagonist_ratio	Kidney	Human	367	AR	Loss	26.99 μM
TOX21_TR_LUC_GH3_Antagonist	Pituitary gland	Rat	7067\|7068	THRA\|THRB	Loss	62.84 μM
TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881	Breast	Human	367	AR	Loss	5.48 μM
TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2	Breast	Human	2099	ESR1	Loss	28.54 μM
TOX21_ERR_LUC_Antagonist	Kidney	Human	2101	ESRRA	Loss	38.67 μM
TOX21_PGC_ERR_LUC_Antagonist	Kidney	Human	2101	ESRRA	Loss	45.68 μM
TOX21_PR_BLA_Antagonist_ratio	Kidney	Human	5241	PGR	Loss	37.74 μM
TOX21_p450_CYP3A4_Antagonist		Human	1576	CYP3A4	Loss	56.97 μM
TOX21_p450_CYP2C19_Antagonist		Human	1557	CYP2C19	Loss	1.2 μM
TOX21_p450_CYP2C9_Antagonist		Human	1559	CYP2C9	Loss	3.12 μM
TOX21_AR_BLA_Antagonist_ratio	Kidney	Human	367	AR	Loss	41.52 μM
TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881	Breast	Human	367	AR	Loss	6.44 μM
TOX21_ERR_LUC_Antagonist	Kidney	Human	2101	ESRRA	Loss	40.76 μM
TOX21_PGC_ERR_LUC_Antagonist	Kidney	Human	2101	ESRRA	Loss	29.35 μM
TOX21_PR_BLA_Antagonist_ratio	Kidney	Human	5241	PGR	Loss	47.24 μM
TOX21_PXR_LUC_Agonist	Liver	Human	8856	NR1I2	Gain	46.08 μM
TOX21_p450_CYP3A4_Antagonist		Human	1576	CYP3A4	Loss	57.47 μM
TOX21_p450_CYP2C19_Antagonist		Human	1557	CYP2C19	Loss	1.37 μM
TOX21_p450_CYP2C9_Antagonist		Human	1559	CYP2C9	Loss	2.86 μM

ToxCast endpoints for intended target type: Molecular messenger

Assay Name	Tissue	Organism	Target Gene ID	Target HGNC Symbol	Response	AC50 Value
CEETOX_H295R_11DCORT	Adrenal gland	Human	2908\|4306	NR3C1\|NR3C2	Inhibitory	34.45 μM
CEETOX_H295R_OHPREG	Adrenal gland	Human	5241	PGR	Inhibitory	50.0 μM
CEETOX_H295R_CORTISOL	Adrenal gland	Human	2908\|4306	NR3C1\|NR3C2	Inhibitory	36.33 μM
CEETOX_H295R_DOC	Adrenal gland	Human	2908\|4306	NR3C1\|NR3C2	Inhibitory	13.38 μM
CEETOX_H295R_ESTRADIOL	Adrenal gland	Human	2099\|2100	ESR1\|ESR2	Activatory	50.0 μM
CEETOX_H295R_ESTRONE	Adrenal gland	Human	2099\|2100	ESR1\|ESR2	Inhibitory	50.0 μM
CEETOX_H295R_PROG	Adrenal gland	Human	5241	PGR	Inhibitory	1.57 μM

ToxCast endpoints for intended target type: Pathway

Assay Name	Tissue	Organism	Target Gene ID	Target HGNC Symbol	Response	AC50 Value
UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist	Bone	Human	367	AR	Loss	17.67 μM
OT_ER_ERaERa_1440	Kidney	Human	2099	ESR1	Gain	74.95 μM
OT_FXR_FXRSRC1_1440	Kidney	Human	6714\|9971	SRC\|NR1H4	Gain	3.68 μM
ACEA_AR_antagonist_80hr	Prostate	Human	367	AR	Loss	6.73 μM
ACEA_AR_antagonist_80hr	Prostate	Human	367	AR	Loss	58.48 μM
TOX21_FXR_BLA_Antagonist_ratio	Kidney	Human	9971	NR1H4	Loss	19.16 μM
TOX21_ARE_BLA_Agonist_ratio	Liver	Human	4780	NFE2L2	Gain	72.16 μM
TOX21_FXR_BLA_Antagonist_ratio	Kidney	Human	9971	NR1H4	Loss	56.51 μM
TOX21_SHH_3T3_GLI3_LUC_Antagonist	Embryo	Mouse	6469	SHH	Loss	4.37 μM
TOX21_FXR_BLA_Antagonist_ratio	Kidney	Human	9971	NR1H4	Loss	35.79 μM
TOX21_SHH_3T3_GLI3_LUC_Antagonist	Embryo	Mouse	6469	SHH	Loss	9.14 μM

No ToxCast endpoints for intended target type: Cellular

No ToxCast endpoints for intended target type: Hormone

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.